Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR7390 in the Treatment of Metastatic Hormone-Resistant Prostate Cancer That Failed Previous Docetaxel and New Endocrine Therapy

NCT04676607 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.

NCT NCT04676607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR7390 in the Treatment of Metastatic Hormone-Resistant Prostate Cancer That Failed Previous Docetaxel and New Endocrine Therapy
Lead sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase
Phase 2
Overall status
Completed
Start date
December 17, 2020
Completion date
June 12, 2023
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer